Literature DB >> 32871784

Sarcopenia and Frailty in Chronic Liver Damage: Common and Different Points.

Hiroki Nishikawa1,2, Kazunori Yoh3, Hirayuki Enomoto3, Yoshinori Iwata3, Yoshiyuki Sakai3, Kyohei Kishino3, Yoshihiro Shimono3, Naoto Ikeda3, Tomoyuki Takashima3, Nobuhiro Aizawa3, Ryo Takata3, Kunihiro Hasegawa3, Takashi Koriyama3, Yukihisa Yuri3, Takashi Nishimura3, Shuhei Nishiguchi4, Hiroko Iijima3.   

Abstract

AIM: To elucidate the common and different points between sarcopenia and frailty in chronic liver damage (CLD). PATIENTS AND METHODS: Patients with both grip strength decline and skeletal muscle index decline were regarded as sarcopenia. Frailty was defined as a syndrome in which 3 or more of the following criteria were met: i) exhaustion, ii) body weight loss, iii) slow walking speed, iv) muscle weakness, and v) low physical activity.
RESULTS: Sarcopenia and frailty were identified in 52 patients (15.2%) and 46 (13.5%), respectively. The prevalence of sarcopenia and frailty was well stratified according to age and the liver cirrhosis (LC) status. In the multivariate analysis, we identified significant factors for sarcopenia: i) age, ii) LC, iii) body mass index and iv) extracellular water (ECW) to total body water (TBW) ratio, while only the ECW to TBW ratio was significant for frailty.
CONCLUSION: Sarcopenia and frailty in CLD should be separately evaluated. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Sarcopenia; chronic liver damage; common point; different point; frailty

Mesh:

Year:  2020        PMID: 32871784      PMCID: PMC7652432          DOI: 10.21873/invivo.12072

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  50 in total

1.  Growing research on sarcopenia in Asia.

Authors:  Hidenori Arai; Masahiro Akishita; Liang-Kung Chen
Journal:  Geriatr Gerontol Int       Date:  2014-02       Impact factor: 2.730

2.  Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria.

Authors:  Hiroki Nishikawa; Makoto Shiraki; Akira Hiramatsu; Kyoji Moriya; Keisuke Hino; Shuhei Nishiguchi
Journal:  Hepatol Res       Date:  2016-09       Impact factor: 4.288

3.  Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.

Authors:  Maiko Namba; Akira Hiramatsu; Hiroshi Aikata; Kenichiro Kodama; Shinsuke Uchikawa; Kazuki Ohya; Kei Morio; Hatsue Fujino; Takashi Nakahara; Eisuke Murakami; Masami Yamauchi; Tomokazu Kawaoka; Masataka Tsuge; Michio Imamura; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2019-09-04       Impact factor: 7.527

Review 4.  Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis.

Authors:  Chalermrat Bunchorntavakul; K Rajender Reddy
Journal:  Aliment Pharmacol Ther       Date:  2019-11-08       Impact factor: 8.171

5.  Chapter 1 Frailty: Definition, diagnosis, epidemiology.

Authors:  Shosuke Satake; Hidenori Arai
Journal:  Geriatr Gerontol Int       Date:  2020-02       Impact factor: 2.730

Review 6.  Frailty-A promising concept to evaluate disease vulnerability.

Authors:  Ana Rita Ribeiro; Susan E Howlett; Adelaide Fernandes
Journal:  Mech Ageing Dev       Date:  2020-02-20       Impact factor: 5.432

Review 7.  Sarcopenia in Cirrhosis: Looking Beyond the Skeletal Muscle Loss to See the Systemic Disease.

Authors:  Rahima A Bhanji; Aldo J Montano-Loza; Kymberly D Watt
Journal:  Hepatology       Date:  2019-12       Impact factor: 17.425

8.  Development of a simple predictive model for decreased skeletal muscle mass in patients with compensated chronic liver disease.

Authors:  Hiroki Nishikawa; Hirayuki Enomoto; Akio Ishii; Yoshinori Iwata; Yuho Miyamoto; Noriko Ishii; Yukihisa Yuri; Ryo Takata; Kunihiro Hasegawa; Chikage Nakano; Takashi Nishimura; Kazunori Yoh; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Hepatol Res       Date:  2017-01-27       Impact factor: 4.288

9.  Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.

Authors:  Jean-Pierre Zarski; Nathalie Sturm; Jérôme Guechot; Adeline Paris; Elie-Serge Zafrani; Tarik Asselah; Renée-Claude Boisson; Jean-Luc Bosson; Dominique Guyader; Jean-Charles Renversez; Jean-Pierre Bronowicki; Marie-Christine Gelineau; Albert Tran; Candice Trocme; Victor De Ledinghen; Elisabeth Lasnier; Armelle Poujol-Robert; Frédéric Ziegler; Marc Bourliere; Hélène Voitot; Dominique Larrey; Maria Alessandra Rosenthal-Allieri; Isabelle Fouchard Hubert; François Bailly; Michel Vaubourdolle
Journal:  J Hepatol       Date:  2011-07-23       Impact factor: 25.083

10.  Frailty and the Burden of Concurrent and Incident Disability in Patients With Cirrhosis: A Prospective Cohort Study.

Authors:  Jennifer C Lai; Jennifer L Dodge; Charles E McCulloch; Kenneth E Covinsky; Jonathan P Singer
Journal:  Hepatol Commun       Date:  2019-10-31
View more
  3 in total

1.  Association of the Modified ALBI Grade With Endoscopic Findings of Gastroesophageal Varices.

Authors:  Yuho Miyamoto; Hirayuki Enomoto; Hiroki Nishikawa; Takashi Nishimura; Yoshinori Iwata; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 2.  Sarcopenia and Frailty in Liver Cirrhosis.

Authors:  Hiroki Nishikawa; Shinya Fukunishi; Akira Asai; Shuhei Nishiguchi; Kazuhide Higuchi
Journal:  Life (Basel)       Date:  2021-04-27

3.  Sarcopenia may Influence the Prognosis in Advanced Thyroid Cancer Patients Treated With Molecular Targeted Therapy.

Authors:  Akihiro Nishiyama; Yukiko Staub; Yukio Suga; Mikiya Fujita; Azusa Tanimoto; Koushiro Ohtsubo; Seiji Yano
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.406

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.